How do I treat patients with RRMM after failure of BCMA-targeted therapies?

BCMA-Targeted Therapy in RRMM: Management of Adverse EventsПодробнее

Treating multiple myeloma resistant to BCMA-targeted therapyПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Treatment Options in RRMMПодробнее

Sequencing BCMA Myeloma TherapiesПодробнее

Emerging Therapies to Treat RRMMПодробнее

Managing progression after BCMA-targeted therapy in R/R multiple myelomaПодробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

BCMA-Targeted Therapy in RRMM: Future Challenges and BiTEПодробнее

BCMA-Targeted Therapy in RRMM: Results From the DREAMM-1 TrialПодробнее

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa resultsПодробнее

Future of BCMA-Targeted Therapies in Multiple MyelomaПодробнее

BCMA-Targeted Therapies in Multiple MyelomaПодробнее

Teclistamab - Guest LectureПодробнее

Using BCMA-targeting agents in earlier lines of treatment for multiple myelomaПодробнее

BCMA-targeted Therapies and Multiple MyelomaПодробнее

Outcomes in RRMM: The Modern Treatment Paradigm and BCMAПодробнее

What’s Next for BCMA-Targeted ADCs and CAR-T Therapy in RRMM?Подробнее

Differentiating Types of BCMA-Targeted Therapies in RRMMПодробнее

Potential Sequencing of BCMA-Directed Therapies in RRMMПодробнее